The 36-month beta value for PHAT is also noteworthy at 0.68. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for PHAT is 32.38M, and at present, short sellers hold a 47.37% of that float. The average trading volume of PHAT on September 12, 2024 was 787.40K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PHAT) stock’s latest price update
Phathom Pharmaceuticals Inc (NASDAQ: PHAT)’s stock price has surge by 4.12relation to previous closing price of 18.70. Nevertheless, the company has seen a 8.47% surge in its stock price over the last five trading sessions. globenewswire.com reported 2024-08-29 that FLORHAM PARK, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in September:
PHAT’s Market Performance
PHAT’s stock has risen by 8.47% in the past week, with a monthly rise of 59.98% and a quarterly rise of 79.12%. The volatility ratio for the week is 5.90% while the volatility levels for the last 30 days are 6.82% for Phathom Pharmaceuticals Inc The simple moving average for the last 20 days is 27.64% for PHAT stock, with a simple moving average of 91.69% for the last 200 days.
Analysts’ Opinion of PHAT
Many brokerage firms have already submitted their reports for PHAT stocks, with Stifel repeating the rating for PHAT by listing it as a “Buy.” The predicted price for PHAT in the upcoming period, according to Stifel is $24 based on the research report published on May 03, 2024 of the current year 2024.
Needham, on the other hand, stated in their research note that they expect to see PHAT reach a price target of $26, previously predicting the price at $23. The rating they have provided for PHAT stocks is “Buy” according to the report published on January 05th, 2024.
H.C. Wainwright gave a rating of “Buy” to PHAT, setting the target price at $28 in the report published on August 09th of the previous year.
PHAT Trading at 50.68% from the 50-Day Moving Average
After a stumble in the market that brought PHAT to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 4.06% of gains for the given period.
Volatility was left at 6.82%, however, over the last 30 days, the volatility rate increased by 5.90%, as shares surge +56.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +89.76% upper at present.
During the last 5 trading sessions, PHAT rose by +8.36%, which changed the moving average for the period of 200-days by +162.84% in comparison to the 20-day moving average, which settled at $15.60. In addition, Phathom Pharmaceuticals Inc saw 113.25% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHAT starting from Nabulsi Azmi, who sale 10,901 shares at the price of $11.72 back on Jul 15 ’24. After this action, Nabulsi Azmi now owns 240,421 shares of Phathom Pharmaceuticals Inc, valued at $127,760 using the latest closing price.
Henderson Molly, the CFO and CBO of Phathom Pharmaceuticals Inc, sale 4,325 shares at $11.72 during a trade that took place back on Jul 15 ’24, which means that Henderson Molly is holding 99,447 shares at $50,689 based on the most recent closing price.
Stock Fundamentals for PHAT
Current profitability levels for the company are sitting at:
- -25.49 for the present operating margin
- 0.83 for the gross margin
The net margin for Phathom Pharmaceuticals Inc stands at -29.96. The total capital return value is set at -0.93. Equity return is now at value -3489.00, with -101.68 for asset returns.
Based on Phathom Pharmaceuticals Inc (PHAT), the company’s capital structure generated 1.86 points at debt to capital in total, while cash flow to debt ratio is standing at -0.43. The debt to equity ratio resting at -2.17. The interest coverage ratio of the stock is -6.68.
Currently, EBITDA for the company is -159.05 million with net debt to EBITDA at -0.92. When we switch over and look at the enterprise to sales, we see a ratio of 156.78. The receivables turnover for the company is 0.91for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.48.
Conclusion
In summary, Phathom Pharmaceuticals Inc (PHAT) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
